title: Adjunctive therapy for neonatal abstinence syndrome: why not personalize it for each infant based on their in-utero exposure?
authors: 1] Division of Neonatology, Department of Pediatrics, Baystate Children's Hospital, Springfield, MA, USA [2] Department of Pediatrics, Tufts University School of Medicine, Boston, MA, USA.
authors: R
authors: R
authors: Singh
authors: 1] Department of Epidemiology, Baystate Medical Center, Springfield, MA, USA [2] Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.
authors: P F
authors: PF
authors: Visintainer
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists / Q000627:therapeutic use*; D000701:Analgesics, Opioid / Q000009:adverse effects*; D003000:Clonidine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009020:Morphine / Q000008:administration & dosage*; D009357:Neonatal Abstinence Syndrome / Q000188:drug therapy*; D010634:Phenobarbital / Q000627:therapeutic use*
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000701:Analgesics, Opioid; D009020:Morphine; D003000:Clonidine; D010634:Phenobarbital